- Home
- PAX vs FULC Comparison
PAX vs FULC Comparison
Compare PAX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAX | FULC |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 707.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PAX | FULC |
|---|---|---|
| Price | $13.81 | $10.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $20.00 | $16.38 |
| AVG Volume (30 Days) | ★ 1.3M | 624.0K |
| Earning Date | 02-03-2026 | 02-27-2026 |
| Dividend Yield | ★ 4.31% | N/A |
| EPS Growth | ★ 16.04 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $381,700,000.00 | N/A |
| Revenue This Year | $17.51 | N/A |
| Revenue Next Year | $16.12 | N/A |
| P/E Ratio | $25.67 | ★ N/A |
| Revenue Growth | 2.00 | ★ 2752.05 |
| 52 Week Low | $9.43 | $2.32 |
| 52 Week High | $17.80 | $15.74 |
Technical Indicators
Market Signals| Indicator | PAX | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 31.96 | 55.58 |
| Support Level | $13.70 | $10.04 |
| Resistance Level | $14.94 | $11.09 |
| Average True Range (ATR) | 0.67 | 0.62 |
| MACD | -0.13 | 0.09 |
| Stochastic Oscillator | 5.82 | 86.91 |
Price Performance
Historical ComparisonAbout PAX Patria Investments Limited
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.